Therapy safety

With new types of therapy or new combinations of therapy it is important to study safety of the therapy. In addition to obvious clinical parameters such as liver enzymes (ALT, AST) or inflammation markers (CRP), one might also consider to study development of auto-antibodies (Serology+ link), formation of anti-drug antibodies (Drug levels and anti-drug levels), induction of a disbalance in immune cells (e.g. T regulatory /T conventional cells or CD4/CD8 T cells) (Cellular Immunophenotyping), etc. We can provide you with the assays needed to understand potential toxicity of your new drug.

Contact us for more information or browse through our assays

Also see:

Last edited on: 29 October 2015